Histamine: A novel approach to cancer immunotherapy

被引:40
作者
Hellstrand, K
Brune, M
Naredi, P
Mellqvist, UH
Hansson, M
Gehlsen, KR
Hermodsson, S
机构
[1] Gothenburg Univ, Dept Virol, S-41346 Gothenburg, Sweden
[2] Gothenburg Univ, Dept Hematol, S-41346 Gothenburg, Sweden
[3] Gothenburg Univ, Dept Surg, S-41346 Gothenburg, Sweden
[4] Maxim Pharmaceut, San Diego, CA USA
关键词
D O I
10.3109/07357900009012178
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The functions of intratumoral lymphocytes in many human malignant tumors are inhibited by reactive oxygen species (ROS), generated by adjacent monocytes/macrophages (MO). In vitro data suggest that immunotherapeutic cytokines such as interleukin-2 (IL-2) or interferon-alpha (IFN-alpha) only weakly activate T cells or natural killer (NK) cells in a reconstituted environment of oxidative stress and that inhibitors of the formation of ROS or scavengers of ROS synergize with IL-2 and IFN-alpha to activate T cells and NK cells. In this review, we focus on the immunoenhancing properties of histamine, a biogenic amine. Histamine inhibits ROS formation in MO via H2-receptors; thereby, histamine protects NK cells from MO-mediated inhibition and synergizes with IL-2 and IFN-alpha to induce killing of NK cell-sensitive human tumor cells in vitro. Histamine also optimizes cytokine-induced activation of several subsets of T cells by affording protection against MO-inflicted oxidative inhibition. The putative clinical benefit of histamine as an adjunct to immunotherapy with IL-2 and/or IFN-alpha is currently evaluated in clinical trials in metastatic malignant melanoma and acute myelogenous leukemia.
引用
收藏
页码:347 / 355
页数:9
相关论文
共 57 条
[41]  
MATSUYAMA S, 1995, ADV CELL MOL BIOL M, V4, P61
[42]   THERAPY OF COLORECTAL-CARCINOMA WITH MONOCLONAL-ANTIBODIES (MAB17-1A) ALONE AND IN COMBINATION WITH GRANULOCYTE MONOCYTE-COLONY STIMULATING FACTOR (GM-CSF) [J].
MELLSTEDT, H ;
FRODIN, JE ;
RAGNHAMMAR, P ;
MASUCCI, G ;
LJUNGBERG, A ;
HJELM, AL ;
FAGERBERG, J ;
LINDEMALM, C ;
OSTERBORG, A ;
WERSALL, P ;
CHRISTENSSON, B ;
SHETYE, J ;
BIBERFELD, P ;
MAKOWER, J ;
CEDERMARK, B ;
ERWALD, R ;
NATHANSSON, J ;
MAGNUSSON, I ;
RIEGER, A .
ACTA ONCOLOGICA, 1991, 30 (08) :923-931
[43]  
MELONI G, 1997, CANCER J SCI AM, V3, P43
[44]  
MITCHELL MS, 1992, SEMIN ONCOL, V19, P80
[45]   ALTERATIONS IN SIGNAL TRANSDUCTION MOLECULES IN LYMPHOCYTES-T FROM TUMOR-BEARING MICE [J].
MIZOGUCHI, H ;
O'SHEA, JJ ;
LONGO, DL ;
LOEFFLER, CM ;
MCVICAR, DW ;
OCHOA, AC .
SCIENCE, 1992, 258 (5089) :1795-1798
[46]  
NAKAGOMI H, 1993, CANCER RES, V53, P5610
[47]  
Nielsen HJ, 1998, GI CANCER, V2, P227
[48]  
OLDHAM RK, 1992, MOL BIOTHER, V4, P4
[49]  
RIZELL M, 1997, INT J MICROCIRC, V17, P98
[50]  
Shepherd J. D., 1994, British Journal of Haematology, V87, P205